Erratum

Supplements and Featured Publications, Clinical Advance in the Management of Febrile Neutropenia ,

In the October 2017 Perspectives in Febrile Neutropenia supplement to The American Journal of Managed Care®, Table 2 in the article entitled “Guidelines in the Management of Febrile Neutropenia for Clinical Practice” (page 11) misstated information regarding the Multinational Association of Supportive Care in Cancer (MASCC) febrile neutropenia risk index.

In the October 2017 Perspectives in Febrile Neutropenia supplement to The American Journal of Managed Care® (AJMC®), Table 2 in the article entitled “Guidelines in the Management of Febrile Neutropenia for Clinical Practice” (page 11) misstated information regarding the Multinational Association of Supportive Care in Cancer (MASCC) febrile neutropenia risk index.1 A MASCC risk index greater than 21 is low risk, not high risk. Additionally, a MASCC risk index less than or equal to 21 is high risk, not low risk. The table has been corrected on the AJMC® website.

1. Klastersky J, de Naurois J, Rolston K, et al; ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118.